Information provided here applies to grants to support independent medical education, scientific and medical associations, independent investigators, institutions, organizations, and academic centers.

Sage maintains a standard of ethical business conduct precluding any inappropriate influence on the content of funded programs. We do not use funding or other support as a means of improperly influencing or gaining favor with others.



Medical Educational Areas of Interest

Disease States

  • Major Depressive Disorder (MDD)
  • Postpartum Depression (PPD)
  • Huntington’s Disease (HD)
  • Parkinson’s Disease (PD)
  • Alzheimer’s Disease (AD)

Depression Franchise

  • Major Depressive Disorder (MDD)
    • Advances in the understanding of the pathophysiology of MDD
    • Understanding neuroactive steroids (NAS) and their potential role in MDD and PPD
    • Impact on GABA-A receptor modulation
    • Understanding burden of MDD disease and current treatments
    • Impact of delayed and/or suboptimal treatment on patient outcomes
    • Future treatment landscape of MDD defining optimal patient outcomes, including potential role for rapid acting treatment of MDD
    • Patient perspectives on burden of disease and management of MDD
  • Postpartum Depression (PPD)
    • Impact of delayed diagnosis and treatment on PPD
    • Understanding burden of PPD, current and future treatments and outcomes
    • Review of clinical and real-world evidence supporting current and future treatments for PPD
  • Impact of COVID-19 on MDD and PPD
  • Education for HCPs, including but not limited to the following audiences:
    • Psychiatry/Primary Care Mental Health Specialists (MDD/PPD)
    • OB/GYN / Maternal Fetal Medicine (PPD)
  • Format (to support broad, interactive education)
    • US-based grant applications
    • Digital-Enduring
    • Live education with enduring component

Neuropsychiatry Franchise

  • Huntington’s Disease (HD)
    • The hypothesized implications of NMDA neuropathology in HD
    • NMDA neurobiology and pharmacology, including as it relates to cognitive improvement
    • Clinical phenomenology (e.g., impact on executive functioning) of mild cognitive impairment in HD and the impact of delayed treatment for cognitive impairment in HD
    • Cholesterol dysregulation and the hypothesized role of neuroactive steroids (NAS) in HD
    • Current/future treatment landscape for non-motor/movement aspects of HD
    • Multi-systemic nature of HD and impact of multidisciplinary diagnosis and management
  • Parkinson’s Disease (PD)
    • Cognitive symptoms and current/future treatment landscape in PD
    • Clinical phenomenology (e.g., impact on executive functioning) in PD
    • Impact of delayed treatment for cognitive impairment in PD
    • Assessment and diagnosis of MCI/cognitive changes in PD
  • Alzheimer’s Disease (AD)
    • Understanding the frequency and magnitude of executive functioning deficits across the spectrum of AD (sub-clinical, MCI, dementia)
    • Impact of delayed treatment of cognitive symptoms associated with AD
    • Understanding cognitive symptoms and current treatments in AD
  • Education for HCPs, including but not limited to the following audiences:
    • Movement Disorder Specialists, Neurologists and Psychiatrists
  • Format (to support broad, interactive education)
    • US-based grant applications
    • Digital-Enduring
    • Live education with enduring component


Educational Grant Funding Requirements

Educational Grant requests must conform to the following:

  • Grant requests must be unsolicited, should typically have multiple funders, and must not provide nor promise any benefit to Sage.
  • Educational programs, activities, or materials that are designed to promote the institution’s or organization’s bona fide patient or educational services must relate to an area of interest to Sage.
  • Educational programs must be scientifically rigorous, balanced, free from commercial influence or bias, and conducted in accordance with industry codes.
  • Funding amounts must be reasonable for the activities proposed and grant funds must only be used for the expenses described in the grant application and the approval agreement.

Educational Grant requests may NOT:

  • Be payable to an individual HCP or physician practice, or companies predominantly owned by a practicing individual HCP or his/her spouse, or the charitable arm thereof
  • Request use of funding to support conference travel grants or registration fees for HCPs (other than funding of scholarships to permit medical students, residents, fellows or other HCPs in training to attend carefully selected educational conferences without naming the recipient)
  • Be for education that is routine and/or a required part of medical training, e.g. textbooks, journal subscriptions, or preparation materials for Board reviews



Timing / Review Process / Decision for Educational Grants

In 2022, grant submissions will be reviewed on a quarterly basis. Below are timeframes for the quarterly reviews and corresponding submission deadlines:

  • Q1 Grants submission deadline: January 15th
    • Q1 Grants review: Mid-March
  • Q2 Grants submission deadline: April 1st
    • Q2 Grants review: Mid-June
  • Q3 Grants submission deadline: July 1st
    • Q3 Grants review: Mid-September
  • Q4 Grants submission deadline: October 1st
    • Q4 Grants review: Mid-December

To submit a new educational grant request please click here.

Funding decisions for grants are made through a formal, centralized grant review and decision-making process.

In all cases, Sage notifies applicants of decisions by email. All applications receive a fair review, and we encourage organizations to reapply for future programs and initiatives.


Investigator Initiated Research (IIR) Grants

Sage Therapeutics is committed to furthering our scientific and clinical understanding of life-altering disorders of the central nervous system (CNS) and overall brain health.

Investigator Initiated Research (IIR) is research that is initiated, sponsored and conducted by an external investigator or institution. IIR opportunities may be submitted to Sage for consideration of funding and/or drug supply. The IIR program is managed by Sage’s internal IIR Committee and governed by Sage’s Funding & Giving Policy.


Brexanolone IIR Areas of Interest (AOIs)

  • Women’s Health
    • Postpartum Depression Prophylaxis (History of Depression)
    • Postpartum Psychosis
    • Postpartum Obsessive-Compulsive Disorder (OCD)
    • Antenatal Depression (treatment initiation postpartum day 1 or 2 for antenatal onset of depression)
  • PPD Well-being & Functioning
    • Mother/Family Health-related Quality of Life (HRQoL) and Functioning
    • Child (Well Baby Outcomes)
    • Effects on sleep architecture
  • Other Neuropsychiatric and Neurologic Conditions (e.g., tinnitus, acute Post-traumatic stress disorder, Panic Disorder, COVID-19 infection-related neurological sequelae, involuntary speech disorders, substance abuse disorders, catatonia)
  • Preclinical (e.g. imaging, neuronal remodeling, signaling pathways)


IIR Grant Funding Requirements

  • Completed Concept
  • High-level budget request
  • Documented PI qualifications (CV, license)

Submit an IIR grant request by downloading our form below.


Email the completed form to